Response to antiseizure medications in neonates with acute symptomatic seizures

Area of Science:

• Neonatal Neurology
• Clinical Pharmacology
• Pediatric Epilepsy

Background:

• Neonatal seizures are a critical concern, often requiring prompt pharmacological intervention.
• Antiseizure medications (ASMs) are standard treatment, but their efficacy in neonates is not fully understood.
• Acute symptomatic seizures in neonates present unique challenges due to immature brain development.

Purpose of the Study:

• To evaluate the response rates to initial antiseizure medication (ASM) loading doses in neonates with acute symptomatic seizures.
• To identify factors influencing ASM treatment response in this population.
• To inform future clinical trial designs and therapeutic strategies for neonatal seizures.

Main Methods:

• Prospective cohort study involving 534 neonates diagnosed with acute symptomatic seizures.
• Data collection on patient demographics, seizure etiology, ASM used, dosage, and treatment response.
• Statistical analysis to compare response rates across different variables and etiologies.

Main Results:

• A significant proportion (66%) of neonates exhibited an incomplete response to the initial ASM loading dose.
• Treatment response did not vary based on gestational age, sex, specific ASM, or dosage.
• Seizure etiology influenced response risk, with intracranial hemorrhage showing higher incomplete response rates compared to hypoxic-ischemic encephalopathy, though not reaching statistical significance after adjustments.

Conclusions:

• Initial ASM loading doses are frequently insufficient for neonates with acute symptomatic seizures.
• Seizure etiology may play a role in ASM refractory epilepsy in neonates.
• Future research should consider ASMs across all neonatal seizure etiologies and potentially target refractory cases.